Enanta initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson started Enanta Pharmaceuticals with an Outperform rating and $135 price target.
The company has "unique molecular optimization capabilities" that could translate into a "superior" product profile in a growing field of liver disease competitors, Olson tells investors in a research note.
He believes Phase 2 data in mid-2019 should drive upside while the company's early stage programs provide optionality.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.